Aptamer to IL-17 and use thereof
AssigneesThe University of Tokyo, Zenyaku Kogyo Kabushiki Kaisha
InventorsAkira Ishiguro, Yoshikazu Nakamura, Kazuhiko Haruta, Natsuki Otaki
Life of this patent
Estimating the term…
Abstract
The present invention provides an aptamer that binds to IL-17 to inhibit binding of IL-17 and IL-17 receptor; a complex containing the aptamer and a functional substance (e.g., affinity substance, labeling substance, enzyme, drug delivery medium, drug and the like); a medicament containing the aptamer, or a complex containing the aptamer and a functional substance, a diagnosing drug and labeling agent and the like.
Claims21
An aptamer comprising a sequence represented by the following formula (Ia), which binds to IL-17 to inhibit binding of IL-17 and IL-17 receptor:
- g(M)g(M)g(M)u(M)a′(M)g′(X1)c(M)c(M)g′g(M)a′(X4)g(X5)g(M)a(M)g(X5)u′(F)c(X7)a′(X2)g(X6)u′(F)r(X3)a′(X3)u(M)c(M)g(M)g(M)u′(X7)a′(M)c′(M)c′(M)c′(M) (SEQ ID NO:
- 95)
- wherein
- a, g, c and u are each an RNA wherein the base is adenine, guanine, cytosine and uracil, respectively,
- r is an RNA wherein the base is adenine or guanine,
- a′, g′ and c′ are each an RNA or DNA wherein the base is adenine, guanine and cytosine, respectively,
- u′ is an RNA wherein the base is uracil, a DNA wherein the base is uracil or a DNA wherein the base is thymine,
- parentheses in nucleotide indicate modification of the nucleotide,
- (M) indicates that, when the nucleotide is an RNA, a hydroxyl group at the 2′-position of ribose therein is substituted by an O-methyl group,
- (F) indicates that, when the nucleotide is an RNA, a hydroxyl group at the 2′-position of ribose therein is substituted by a fluorine atom,
- (X1) indicates that nucleotide is non-modified or phosphorothioated, or when the nucleotide is an RNA, a hydroxyl group at the 2′-position of ribose therein is substituted by a fluorine atom,
- (X2) indicates that nucleotide is non-modified, or when the nucleotide is an RNA, a hydroxyl group at the 2′-position of ribose therein is substituted by a fluorine atom,
- (X3) indicates that nucleotide is non-modified, or when the nucleotide is an RNA, a hydroxyl group at the 2′-position of ribose therein is substituted by an O-methyl group,
- (X4) indicates that nucleotide is non-modified, or when the nucleotide is an RNA, a hydroxyl group at the 2′-position of ribose therein is substituted by a fluorine atom or an O-methyl group,
- (X5) indicates that nucleotide is non-modified or phosphorothioated,
- (X6) indicates that nucleotide is non-modified or phosphorothioated, or when the nucleotide is an RNA, a hydroxyl group at the 2′-position of ribose therein is substituted by an O-methyl group, and
- (X7) indicates that when nucleotide is an RNA, a hydroxyl group at the 2′-position of ribose therein is substituted by a fluorine atom or an O-methyl group.
An aptamer comprising a sequence represented by the following formula (II), which binds to IL-17 to inhibit binding of IL-17 and IL-17 receptor:
- g(x1)g(x1)g(x1)u(F)ag(S)c(F)c(F)g′(S)g(x2)aggagu(F)c(F)agu(F)aau(F)c(F)ggu(F)ac′(x3)c′(x3)c′(x3) (SEQ ID NO:
- 99)
- wherein
- a, g, c and u are each an RNA wherein the base is adenine, guanine, cytosine and uracil, respectively,
- g′ and c′ are each an RNA or DNA wherein the base is guanine or cytosine, respectively,
- parentheses in nucleotide indicate modification of the nucleotide,
- (F) indicates that a hydroxyl group at the 2′-position of ribose in the nucleotide is substituted by a fluorine atom,
- (S) indicates that, when nucleotide is an RNA, it is phosphorothioated,
- (x1) indicates that nucleotide is modified with Locked Nucleic Acid (LNA), or when the nucleotide is an RNA, a hydroxyl group at the 2′-position of ribose therein is substituted by an O-methyl group,
- (x2) indicates that nucleotide is non-modified, or when the nucleotide is an RNA, a hydroxyl group at the 2′-position of ribose therein is substituted by an O-methyl group, and
- (x3) indicates that nucleotide is non-modified, or modified with LNA.
Dependencies are inferred from the claim text.